Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reiter

Showing results (411-420 of 426) with videos related to

Pageof 43
Sort By:
Leukemia|March 23, 2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphomaG Metzgeroth, C Walz, J Score, et al.
Leukemia|February 20, 2014
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patientsP Guglielmelli, T L Lasho, G Rotunno, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1Lawrence A Reiter, Ralph P Robinson, Kim F McClure, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2007
Pyrimidine benzamide-based thrombopoietin receptor agonistsLawrence A Reiter, Chakrapani Subramanyam, Emilio J Mangual, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 19, 2026
Towards Clinical Translation of Intravoxel Incoherent Motion MRI: Acquisition and Analysis Consensus RecommendationsEric E Sigmund, Susanne S Rauh, Mami Iima, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
The identification of orally bioavailable thrombopoietin agonistsMichael J Munchhof, Amy S Antipas, Laura C Blumberg, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14Julian A Blagg, Mark C Noe, Lilli A Wolf-Gouveia, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Leukemia|April 27, 2013
Mutations and prognosis in primary myelofibrosisA M Vannucchi, T L Lasho, P Guglielmelli, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Pageof 43

Showing results (411-420 of 426) with videos related to

Sort By:
Pageof 43
Leukemia|March 23, 2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphomaG Metzgeroth, C Walz, J Score, et al.
Leukemia|February 20, 2014
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patientsP Guglielmelli, T L Lasho, G Rotunno, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1Lawrence A Reiter, Ralph P Robinson, Kim F McClure, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2007
Pyrimidine benzamide-based thrombopoietin receptor agonistsLawrence A Reiter, Chakrapani Subramanyam, Emilio J Mangual, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 19, 2026
Towards Clinical Translation of Intravoxel Incoherent Motion MRI: Acquisition and Analysis Consensus RecommendationsEric E Sigmund, Susanne S Rauh, Mami Iima, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
The identification of orally bioavailable thrombopoietin agonistsMichael J Munchhof, Amy S Antipas, Laura C Blumberg, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14Julian A Blagg, Mark C Noe, Lilli A Wolf-Gouveia, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Leukemia|April 27, 2013
Mutations and prognosis in primary myelofibrosisA M Vannucchi, T L Lasho, P Guglielmelli, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Pageof 43